The BioMedWire Podcast Featuring Robert Thast, CEO of Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) [Video Edition]

AUSTIN, Texas, September 4, 2025 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Robert Thast, CEO of Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers.

To begin the interview, Thast discussed Izotropic’s mission: commercializing its FDA-aligned IzoView Breast CT Imaging System to close critical gaps in early cancer detection.

“Screening is the first line of defense; it’s where lives are saved or not. Current standard of care misses a lot of cancers and is not particularly good at finding aggressive cancers in the early stages. With our Breast CT technology, we can see cancers as small as 2 millimeters. Current standard of care is 11 millimeters average. That’s a big difference—between 12 and 18 months earlier—which could mean the difference between finding it and treating it or having it get past the point of no return.”

Thast also spoke to Izotropic’s intellectual property strategy, competitive outlook, and long-term positioning in the imaging space.

“We have recently announced an AI development and capability that no one else has and may never have. We expect this technology will become increasingly accepted over time, and the majors will have to get involved if they intend to maintain their market share… In terms of protecting our position, we have a portfolio of patents, trade secrets, and products… The majors are certainly going to have the muscle to get in the game — there’s no question about that. I think it’d be a lot less expensive for them to buy something like IzoView, and I expect that’s what will happen as we move forward. We believe we will be a takeover target.”

He then outlined Izotropic’s commercialization strategy, including a phased rollout in Europe and the U.S., supported by clinical validation and significant early demand.

“From a revenue standpoint, our launch will be focused primarily on selling to hospitals, medical facilities, and imaging clinics. Those will be focused on the EU first, followed by the United States… Between the U.S. and Europe, you’re looking at almost 50% of the world market for one of these devices… The FDA study is a clear mandate. If we secure FDA approval, really the world is wide open to us.”

Join IBN’s Carmel Fisher and Robert Thast, CEO of Izotropic Corp., to learn more about the company’s AI-powered precision oncology platform, pipeline milestones, and vision for transforming cancer treatment.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Izotropic

More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca.

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com